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Silencing Innovation: The Patent Eligibility of 
siRNA Therapeutics 
Alexander M. Walker, PhD 
Small interfering ribonucleic acids (siRNAs) are a type of 
nucleic acid capable of initiating the ribonucleic acid interfer-
ence (RNAi) pathway.1 siRNA-induced RNAi creates a gene-si-
lencing effect that can be used to affect the function of difficult-
to-treat diseases and may be especially useful for the treatment 
of certain cancers.2 The silencing effect is created by complemen-
tary recognition of the siRNA sequence and the messenger RNA 
sequence (mRNA) of the target gene.3 Several siRNA-based ther-
apeutics have received approval from the U.S. Food and Drug 
Administration (FDA) to begin clinical trials and one siRNA 
therapeutic has recently received FDA marketing authoriza-
tion.4 
Whether an invention represents a subject matter eligible 
for patenting is determined by 35 U.S.C. § 101,5 which also lists 
 
 1. RNA Interference (RNAi), NAT’L CENTER FOR BIOTECH. INFO., 
https://www.ncbi.nlm.nih.gov/probe/docs/techrnai/ (last visited Oct. 27, 2018). 
 2. See Sherry Y. Wu et al., Targeting the Undruggable: Advances and Ob-
stacles in Current RNAi Therapy, SCI. TRANSLATIONAL MED., June 2014, at 1, 
1 (“[An siRNA] approach has attracted particular interest within oncology, 
where many important targets have proven undruggable.”). 
 3. See Ashley J. Pratt & Ian J. MacRae, The RNA-Induced Silencing Com-
plex: A Versatile Gene-Silencing Machine, 284 J. BIOLOGICAL CHEMISTRY 17897, 
at 17899 (2009) (“[T]he [siRNA] guide strand form[s] a Watson-Crick-paired, A-
form double helix with a complementary region of the target RNA.”); see also 
discussion of complementary binding infra Section I.A. 
 4. See Chiranjib Chakraborty et al., Therapeutic miRNA and siRNA: Mov-
ing from Bench to Clinic as Next Generation Medicine, 8 MOLECULAR THERAPY 
NUCLEIC ACIDS 132, 132 (2017); FDA Approves First-Of-Its Kind Targeted RNA-
Based Therapy to Treat a Rare Disease, U.S. FOOD & DRUG ADMIN. (Aug. 10, 
2018), https://www.fda.gov/news-events/press-announcements/fda-approves-
first-its-kind-targeted-rna-based-therapy-treat-rare-disease [hereinafter RNA-
Based Therapy] (“To date, approximately 20 clinical trials have been initiated 
using miRNA- and siRNA-based therapeutics.”). 
 5. See, e.g., Ass’n for Molecular Pathology v. Myriad Genetics, Inc., 569 
U.S. 576, 595 (2013). 
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the statutory categories available to patentees.6 Patent eligibil-
ity has traditionally foreclosed certain subject matter called “ju-
dicial exceptions,”7 which includes laws of nature, natural phe-
nomena, and abstract ideas.8 The patenting of deoxyribonucleic 
acids (DNA) began in force following the Supreme Court’s deci-
sion in Diamond v. Chakrabarty.9 Following this decision, DNA 
sequences (including genomic DNA) were routinely patented10 
until key court rulings held many types of DNA patents ineligi-
ble for patenting.11 However, no case law has directly addressed 
the patent eligibility of DNA or ribonucleic acid (RNA) therapeu-
tics.12 
The goal of this note is to explore the patent eligibility of 
siRNA therapeutics. Part I of this note discusses the molecular 
mechanism of siRNA, the judicial exceptions to 35 U.S.C. § 101, 
relevant case law on the patent eligibility of DNA molecules, and 
the general economic effects of patent protection. Though there 
is no case law directly addressing the patent eligibility of RNA 
molecules, applying holdings on DNA molecules to siRNA sug-
gests that it has limited patent eligibility, potentially only as 
part of a “method of treatment” claim,13 as discussed in Part II 
 
 6. 35 U.S.C. § 101 (1952). 
 7. CLS Bank Int’l v. Alice Corp. Pty. Ltd., 717 F.3d 1269, 1277 (Fed. Cir. 
2013), aff’d, 573 U.S. 208 (2014) (“If the invention falls within one of the statu-
tory categories, we must then determine whether any of the three judicial ex-
ceptions nonetheless bars such a claim.”). 
 8. Diamond v. Diehr, 450 U.S. 175, 185 (1981). 
 9. See Aaron S. Kesselheim, Gene Patenting—The Supreme Court Finally 
Speaks, 369 NEW ENG. J. MED. 869, 871 (2013) (Discussing “[t]he landmark 
1980 case of Diamond v. Chakrabarty, which ushered in the modern explosion 
in biotechnology patents.”). 
 10. See, e.g., Vincent Y. Ling, Patently Ours? Constitutional Challenges to 
DNA Patents, 14 U. PA. J. CONST. L. 813, 813 (2012) (“Since [1980], the PTO has 
granted over 40,000 patents on DNA.”). 
 11. See, e.g., Myriad, 569 U.S. at 577. 
 12. See Roche Molecular Sys., Inc. v. CEPHEID, 905 F.3d 1363, 1373 n.6 
(Fed. Cir. 2018) (“We express no opinion on subject matter eligibility of method 
claims that exploit DNA or RNA for drug-like new applications.”); see also Rob-
ert W. Esmond & Alex Kwan-Ho Chung, The Patent Landscape of siRNA Nano-
particle Delivery, 11 NANOTECH. L. & BUS. 15, 26–27 (2014) (describing litiga-
tion of siRNA as dealing with inventorship, patent malpractice, and trade secret 
disputes). 
 13. See, e.g., Vanda Pharm. Inc. v. W.-Ward Pharm. Int’l Ltd., 887 F.3d 
1117, 1136 (Fed. Cir. 2018), petition for cert. filed, 87 U.S.LW. 3279 (U.S. Jan. 
17, 2019) (No. 18-817). 
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of this note. However, siRNA represents a significant area of po-
tential biopharmaceutical investment14 and offers numerous 
medical advantages over conventional therapeutics.15 Therefore, 
Part III of this note offers an alternative interpretation of DNA 
case law that could expand the statutory categories available to 
potential siRNA patents as well as a legislative solution capable 
of offering non-patent market exclusivity. 
I. BACKGROUND 
Part I of this note will begin by giving a brief primer on the 
scientific principles underlying siRNA before transitioning into 
an overview of patentable subject matter. It will then explore 
case law interpreting 35 U.S.C. § 101 with a focus on holdings 
related to nucleotide technologies.16 Further, this section will 
provide context on the patent landscape of siRNA therapeutics 
and the forecasted economy of siRNA technologies. 
A. A BRIEF PRIMER ON NUCLEOTIDES 
Structurally, DNA generally possesses four types of nucleo-
tide bases: adenine, thymine, guanine, and cytosine.17 RNA, a 
closely related biological macromolecule, contains uracil in lieu 
of thymine, but otherwise shares the same bases as DNA.18 The 
sequence of nucleotide bases possessed by a given DNA or RNA 
molecule is generally referred to as its “sequence.”19 Further, nu-
cleotides have directionality imparted by the presence of a phos-
phate group at one end (referred to as the 5’ end) and a free hy-
droxyl group at the other (referred to as the 3’ end) of each 
 
 14. Chakraborty et al., supra note 4, at 134 (“[B]iopharma companies are 
investing in the development of miRNA- and siRNA-based therapeutic mole-
cules. However, there is a challenge for small biotechnology companies because 
there is some financial volatility in this area.”). 
 15. Cf. Novartis and UC Berkeley Take on “Undruggable” Proteins in New 
Collaboration, NOVARTIS: STORIES (Sept. 28, 2017), https://www.novar-
tis.com/stories/discovery/novartis-and-uc-berkeley-take-undruggable-proteins-
new-collaboration (Explaining that most proteins, and thus most disease tar-
gets, are undruggable) [hereinafter Novartis] (internal quotation marks omit-
ted). 
 16. See, e.g., Myriad, 569 U.S. at 594–95 (holding that cDNA is patent-eli-
gible subject matter and that genomic DNA is not). 
 17. E.g., DNA and RNA, JEFFERSON, https://cm.jefferson.edu/learn/dna-
and-rna/ (last visited Feb. 13, 2019). 
 18. E.g., id. 
 19. E.g., id. (“It is the sequence of these four bases along the backbone that 
encodes information.”). 
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nucleic acid molecule.20 Because longer nucleotide strands are 
polymers formed of repeating nucleotide units, they also have 5’ 
and 3’ ends.21 
DNA is generally double-stranded, while RNA is often (but 
not always) single-stranded.22 Two DNA or RNA strands inter-
act with one another through hydrogen bonds formed between 
their respective bases. Double-stranded DNA or RNA molecules 
generally have an anti-parallel structure, wherein the individual 
strands run parallel but in opposite directions.23 The process by 
which two nucleotide bases bond is generally referred to as “com-
plementary base-pairing.”24 Moreover, base-pairing tends to oc-
cur in a predictable regime—adenine base-pairs with thymine 
(or uracil, in the case of RNA) and guanine base-pairs with cyto-
sine.25 When all of the bases of two DNA or RNA strands are able 
to base-pair, those two sequences are also said to be “complemen-
tary” or “fully complementary.”26 Strands that are not fully com-
plementary but still have some bases engaging in complemen-
tary base-pairing are said to be “partially” complementary.27 
Notably, not all of the DNA within a given genome codes for 
a protein or another functional gene product.28 Following RNA 
transcription, in which an RNA strand is synthesized from a 
template DNA strand, a process called “RNA splicing” removes 
 
 20. E.g., DNA, UNI. OF QUEENSL.: DIAMANTINA INST., 
https://di.uq.edu.au/community-and-alumni/sparq-ed/sparq-ed-services/dna 
(last visited Feb. 13, 2019). 
 21. See id. 
 22. See DNA and RNA, supra note 17. 
 23. E.g., id. 
 24. E.g., id. 
 25. E.g., id. 
 26. See, e.g., id.; see also, e.g., Akira Shimizu et al., Characterisation of Cy-
toplasmic DNA Complementary to Non-Retroviral RNA Viruses in Human Cells, 
NATURE SCI. REP., May 30, 2014, at 1, 2 (describing an RNA-DNA binding in-
teraction as “fully complementary”). 
 27. See, e.g., Susanna Monti et al., Complementary and Partially Comple-
mentary DNA Duplexes Tethered to a Functionalized Substrate: A Molecular 
Dynamics Approach to Biosensing, 13 PHYSICAL CHEMISTRY CHEM. PHYSICS 
12479, 12478 (2011) (describing mismatched DNA sequences as “partially com-
plementary”). 
 28. See, e.g., Transcription, Translation and Replication, ATDBIO, 
https://www.atdbio.com/content/14/Transcription Translation-and-Replication 
(last visited Feb. 13, 2019). 
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the noncoding regions, called “introns,” from the coding regions, 
called “exons.”29 
B. THE TECHNOLOGY ITSELF: HOW DOES SIRNA WORK? 
Though RNAs are perhaps best known by the role that 
mRNA30 plays in gene expression as an intermediary between 
DNA and protein,31 other forms of RNA molecules have a wide 
range of functional and regulatory roles.32 RNA interference 
(RNAi) is a natural mechanism of regulating gene expression 
that utilizes small RNA sequences33 and may have an “im-
portant role in pathogen resistance.”34 Generally, the process of 
using RNAi to affect gene expression is known as “silencing.”35 
The RNAi pathway is sensitive to “trigger RNA” molecules, most 
commonly either pri-microRNA (pri-miRNA)36 or double-
stranded RNA (dsRNA).37 The pre-miRNAs are expressed natu-
rally in mammalian cells, typically have a short-hairpin struc-
ture, and are processed by the cell into pre-miRNA that is then 
processed into miRNA.38 Unlike pre-miRNA, dsRNA precursors 
 
 29. See, e.g., id. 
 30. See, e.g., What is RNA?, THE RNA SOC’Y, https://www.rnaso-
ciety.org/about/ (last visited Nov. 18, 2018) (“A central tenet of molecular biol-
ogy states that the flow of genetic information in a cell is from DNA through 
RNA to proteins . . . .”). 
 31. See, e.g., Gene Expression, NAT’L CANCER INST.: DICTIONARY OF CAN-
CER TERMS, https://www.cancer.gov/publications/dictionaries/cancer-
terms/def/gene-expression (last visited Nov. 27, 2018) (Defining “gene expres-
sion” as “[t]he process by which a gene gets turned on in a cell to make RNA 
and proteins.”), 
 32. See, e.g., THE RNA SOCIETY, supra note 30 (“In recent years, however, 
we have begun to realize that the roles adopted by RNA are much broader and 
much more interesting.”). 
 33. RNA Interference (RNAi), supra note 1. 
 34. Id. 
 35. Id. 
 36. See generally Louise Adams, Pri-miRNA Processing: Structure Is Key, 
18 NATURE REVS. GENETICS 145, 145 (2017) (explaining that pri-miRNA is pro-
cessed into pre-miRNA, which is transported and processed into mature 
miRNA); see also generally Lin He and Gregory J. Hannon, microRNAs: Small 
RNAs with a Big Role in Gene Regulation, 5 NATURE REVS. GENETICS 522, 524–
25 (2004) (explaining the biogenesis of miRNA). 
 37. See RNA Interference (RNAi), supra note 1. 
 38. See, e.g., Precursor miRNAs for Successful miRNA Functional Studies, 
THERMOFISHER SCI., https://www.thermofisher.com/us/en/home/references/am-
bion-tech-support/microrna-studies/tech-notes/precursor-mirnas-for-success-
ful-mirna-functional-studies.html (last visited Jan. 23, 2019). 
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can be derived from endogenous or exogenous39 sources and are 
processed by the cell into siRNAs.40 
Once processed, miRNA and siRNA are loaded into Argo-
naute (Ago) proteins to form an RNA-induced silencing complex 
(RISC)41 capable of targeting one or more mRNA sequences for 
silencing.42 The sequence of the miRNA or siRNA controls which 
mRNA is recognized as the target mRNA through complemen-
tary interaction.43 Once the RISC complex has bound the target 
sequence, it performs its gene-silencing function through one of 
four major mechanisms: by “slicing” or chemically breaking the 
target RNA, by preventing translation of it into a protein (either 
by blocking access to the target RNA or by targeting the RNA for 
degradation by other enzymes), by modifying the histones asso-
ciated with the locus of the gene encoding the RNA target and 
thereby altering the rate at which the gene is transcribed, or by 
eliminating the DNA encoding the RNA from the genome alto-
gether.44 
There are a number of important differences between 
miRNA and siRNA molecules beyond their structural dissimilar-
ity.45 An miRNA can bind to sequences with which it is only par-
tially complementary, allowing it to target a broad range of se-
quences.46 Conversely, an siRNA must be “fully complementary 
 
 39. “Endogenous” refers to molecules “[a]rising within the organism or 
cell.” E.g., Endogenous, GENSCRIPT: MOLECULAR BIOLOGY GLOSSARY, 
https://www.genscript.com/molecular-biology-glossary/935/endogenous (last 
visited Feb. 13, 2019). “Exogenous” refers to molecules “[a]rising from a source 
outside the organism or cell.” E.g., Exogenous, GENSCRIPT: MOLECULAR BIOL-
OGY GLOSSARY, https://www.genscript.com/molecular-biology-glossary/1013/ex-
ogenous (last visited Feb. 13, 2019). 
 40. Pratt & MacRae, supra note 3 at 17898 (“Silencing RNA can be derived 
from exogenous or intracellular origins . . . .”). 
 41. See RNA Interference (RNAi), supra note 1. 
 42. See Pratt & MacRae, supra note 3, at 17899 (“The core architecture of 
Argonaute and guide RNA allows RISC to efficiently locate specific targets 
within the vast pool of cellular RNAs.”). 
 43. Id. (“[T]he [miRNA or siRNA] guide strand form[s] a Watson-Crick-
paired, A-form double helix with a complementary region of the target RNA.”). 
 44. See id. at 17989–90. 
 45. Even among experts in the field, these differences are sometimes unno-
ticed because “the distinction [between miRNA and siRNA] has been obscured 
because they are associated with common enzymes . . . and their functions over-
lap with each other to a certain extent.” Jenny K.W. Lam et al., siRNA Versus 
miRNA as Therapeutics for Gene Silencing, 4 MOLECULAR THERAPY NUCLEIC 
ACIDS 252, 253 (2015). 
 46. Id. at 254–55. 
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to its target mRNA,” thereby making siRNA-based RNAi highly 
specific.47 Moreover, introducing synthetic siRNA directly to 
mammalian cells (rather than the longer dsRNA precursors) has 
been shown to further increase the specificity of the resulting 
RNAi response.48 Because siRNA is fully complementary to its 
target sequence, it also is able to activate the “slicing” function 
of the siRNA-RISC complex.49 Conversely, miRNA-mediated si-
lencing usually “occurs through translation repression, or degra-
dation by deadenylation, decapping or exonuclease action.”50 At 
least for these reasons, siRNAs have been favored over miRNA 
for therapeutic applications of RNAi-based gene silencing.51 
Further, siRNA-mediated RNAi offers a major improvement 
to conventional therapeutics, especially in the treatment of cer-
tain cancers.52 This is in part due to the ability of siRNA to target 
any given mRNA sequence and only that sequence.53 Moreover, 
siRNA technologies have the capability to affect the expression 
(and thereby the function) of a broad range of genes as compared 
to traditional small molecule drugs—conventional therapeutics 
can only target certain classes of proteins, leaving “some dis-
eases untreatable.”54 By contrast, siRNAs “can downregulate the 
expression of virtually all genes and their mRNA transcripts,” 
significantly broadening the range of treatable targets “[s]ince 
 
 47. Id. at 253. 
 48. See id. (“[D]irect introduction of synthetic siRNAs, instead of the long 
dsRNAs (thus skipping the step of Dicer processing), leads to effective RNAi 
without the complication of activating the IFN response.”). 
 49. See id. at 253–55 (“[T]he guide strand guides the active RISC to its tar-
get mRNA for cleavage by AGO2. As the guide strand only binds to mRNA that 
is fully complementary to it, siRNA causes specific gene silencing.”). 
 50. Id. at 255. 
 51. See id. at 255–56, 264 (describing siRNAs as “extremely useful for tar-
geting single gene disorders” and as having been favored by researchers as po-
tential therapeutics due to the uncertainty surrounding miRNA “mechanism of 
action and specificity”). 
 52. See, e.g., Kevin Bullis, Gene-Silencing Drugs Finally Show Promise, 
MIT TECH. REV. (Sep. 14, 2014), https://www.technolo-
gyreview.com/s/530631/gene-silencing-drugs-finally-show-promise/ (“Treating 
cancer is one area where RNAi’s particular advantages are expected to shine.”). 
 53. See id. (“RNAi can be extremely precise, potentially shutting down only 
proteins found in cancer cells.”). 
 54. Novartis, supra note 15 (internal quotation marks omitted) (quoting 
Dan Nomura, director of the Novartis-Berkeley Center for Proteomics and 
Chemistry Technologies). 
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many diseases result from the expression of undesired or mu-
tated genes, or from overexpression of certain normal genes.”55 
Despite the relative advantages of siRNA therapeutics, delivery 
of siRNA into the cell remains a major challenge.56 
Conventional siRNA therapeutics contain roughly nineteen 
to twenty-one nucleotides identical in sequence to the target 
gene as well as “two nucleotide overhangs at the 3’ end . . . which 
are important for recognition by the RNAi machinery.”57 How-
ever, at least one study has shown that dsRNAs up to twenty-
seven nucleotides in length are significantly “more potent induc-
ers of RNAi than conventional siRNAs.”58 Using dsRNAs with 
thirty or more nucleotides is thought to be undesirable because 
those dsRNAs can “activate[] . . . the interferon pathway,”59 an 
immune system response to pathogen infection.60 
C. THE JUDICIAL EXCEPTIONS TO 35 U.S.C § 101 LIMIT PATENT 
ELIGIBILITY 
Section 101 of the Patent Act establishes the four statutory 
categories of patentable subject matter: processes, machines, ar-
ticles of manufacture, and compositions of matter. 61 However, 
merely reciting subject matter directed to one of the four statu-
tory categories does not guarantee patent eligibility.62 Rather, 
“laws of nature, natural phenomena, and abstract ideas” are 
 
 55. Lam et al., supra note 45, at 255. 
 56. Hassan Dana et al., Molecular Mechanisms and Biological Functions of 
siRNA, INT. J. BIOMED. SCI., June 2017, at 48, 50 (“The fantastic potential of 
siRNA to silence important genes in disease pathways comes with noteworthy 
challenges and barriers in its delivery.”). 
 57. Lam et al., supra note 45, at 255 (citing S. Patrick Walton et al., De-
signing Highly Active siRNAs for Therapeutic Applications, 277 FEBS J. 4806, 
4807 (2010)). 
 58. Dong-Ho Kim et al., Synthetic dsRNA Dicer Substrates Enhance RNAi 
Potency and Efficacy, 23 NATURE BIOTECH. 222, 225 (2005). 
 59. Id. at 222. 
 60. See generally Interferon (IFN) Cell Signaling Pathway, THER-
MOFISHER, https://www.thermofisher.com/us/en/home/life-science/cell-analy-
sis/signaling-pathways/interferon/interferon-overview.html (last visited Mar. 5, 
2019) (“The interferon . . . pathway plays a critical role in the human immune 
response.”). 
 61. See 35 U.S.C. § 101 (1952) (listing, in general terms, subject matter el-
igible for patent). 
 62. See generally U.S. PAT. & TRADEMARK OFF., MPEP § 2104 (9th ed., Rev. 
8, Jan. 2018) (describing four requirements, in addition to inclusion in one of 
these four statutory categories, for a patent application to be valid). 
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generally not patentable.63 These exceptions to are often referred 
to as “judicial exceptions” to § 101’s broad statutory categories64 
and are designated as such because they are rooted in the com-
mon law rather than the statutory language of 35 U.S.C. § 101.65 
The judicial exceptions were developed to prevent the patenting 
of “basic tools of scientific and technological work”66 and concepts 
that are “part of the storehouse of knowledge of all men . . . free 
to all men and reserved exclusively to none.”67 From a policy per-
spective, the judicial exceptions are targeted to prevent patents 
from “reach[ing] too far and claim[ing] too much, on balance ob-
structing rather than catalyzing innovation.”68 Thus, patents 
that simply recite “an instruction to ‘apply the natural law’ . . . 
foreclose[] more future invention than the underlying discovery 
could reasonably justify.”69 However, courts have recognized 
that interpreting the judicial exceptions too broadly could seri-
ously undermine the purpose of patent law because “all inven-
tions at some level embody, use, reflect, rest upon, or apply laws 
of nature, natural phenomena, or abstract ideas.”70 
In order to balance these competing policy interests, the Su-
preme Court has provided a two-step framework, articulated in 
Alice Corp. v. CLS Bank International, to determine if a claim 
that recites subject matter directed to one of the judicial excep-
tions is nonetheless eligible for patenting.71 If a court determines 
 
 63. Diamond v. Diehr, 450 U.S. 175, 185 (1981) (“Excluded from . . . patent 
protection are laws of nature, natural phenomena, and abstract ideas.”). 
 64. CLS Bank Int’l v. Alice Corp. Pty. Ltd., 717 F.3d 1269, 1277 (Fed. Cir. 
2013), aff’d, 573 U.S. 208 (2014) (“If the invention falls within one of the statu-
tory categories, we must then determine whether any of the three judicial ex-
ceptions nonetheless bars such a claim.”); U.S. PAT. & TRADEMARK OFF., supra 
note 62 (“[A] claimed invention must be directed to patent-eligible subject mat-
ter and not a judicial exception . . . .”). 
 65. Bilski v. Kappos, 561 U.S. 593, 601 (2010) (citing Diamond v. 
Chakrabarty, 447 U.S. 303, 309 (1980)) (“The Court’s precedents provide three 
specific exceptions to § 101’s broad patent-eligibility principles: ‘laws of nature, 
physical phenomena, and abstract ideas.’”) (emphasis added). 
 66. Gottschalk v. Benson, 409 U.S. 63, 67 (1972). 
 67. Bilski, 561 U.S. at 602 (quoting Funk Bros. Seed Co. v. Kalo Inoculant 
Co., 333 U.S. 127, 130 (1948)) (internal quotation marks omitted). 
 68. CLS Bank, 717 F.3d at 1277. 
 69. Mayo Collaborative Servs. v. Prometheus Labs., Inc., 566 U.S. 66, 86 
(2012). 
 70. Id. at 71. 
 71. See Alice Corp. Pty. v. CLS Bank Int’l, 573 U.S. 208, 216 (2014) (quoting 
Mayo, 566 U.S. at 84) (“First, we determine whether the claims at issue are 
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that a particular claim or set of claims are directed to one of the 
judicial exceptions, it must examine the elements of the claim to 
determine if there are “additional elements that ‘transform the 
nature of the claim’ into a patent-eligible application.”72 An ad-
ditional element or a combination of additional elements 
amounting to “well-understood, routine, conventional activity,” 
as recognized by a court or a person of ordinary skill in the art, 
is not sufficient to transform a claim directed to a judicial excep-
tion into patent-eligible subject matter.73 Further, claim ele-
ments are considered as a whole, meaning that even where indi-
vidual steps may be well understood, routine, or conventional, 
the combination may “‘transform the nature of the claim’ into a 
patent-eligible application.”74 If the additional element or com-
bination of elements “amounts to significantly more than a pa-
tent upon the [judicial exception] itself,” then the claim is eligi-
ble for patenting.75 
Therapeutics and therapeutic strategies have posed special 
problems for courts interpreting 35 U.S.C. § 101. Methods of di-
agnosis have generally been regarded by both the Supreme 
Court and the Federal Circuit as reciting patent-ineligible sub-
ject matter insofar as such methods often are difficult to distin-
guish from the natural law they are applying.76 However, the 
Federal Circuit recently held that a method of treating schizo-
phrenia using the anti-psychotic drug iloperidone was patent-
 
directed to one of those patent-ineligible concepts. If so, we then ask, ‘What else 
is there in the claims before us?’”). 
 72. Id. at 216. 
 73. Mayo, 566 U.S. at 68 (citing Parker v. Flook, 437 U.S. 584, 590 (1978)) 
(“[Well-understood, routine, or conventional] activity is normally not sufficient 
to transform an unpatentable law of nature into a patent-eligible application of 
such a law.”). 
 74. Alice, 573 U.S. at 211 (quoting Mayo, 566 U.S. at 74); see also Rapid 
Litig. Mgmt. Ltd. v. CellzDirect, Inc., 827 F.3d 1042, 1051 (Fed. Cir. 2016) (quot-
ing Diamond v. Diehr, 450 U.S. 175, 188 (1981)) (“[A] new combination of steps 
in a process may be patentable even though all the constituents of the combina-
tion were well known and in common use before the combination was made.”) 
(internal quotation marks omitted). 
 75. Mayo, 566 U.S. at 73. 
 76. E.g., Ariosa Diagnostics, Inc. v. Sequenom, Inc., 788 F.3d 1371, 1377 
(Fed. Cir. 2015) (holding a method of diagnosis based on “detecting” amplified 
DNA as patent ineligible on the grounds that the method used conventional 
steps to apply a natural law). 
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eligible.77 Because the method at issue recited “using a specific 
compound at specific doses to achieve a specific outcome,” it was 
found to contain “more than the natural relationship” between 
iloperidone and schizophrenia.78 
D. THE MYRIAD GENETICS SAGA: DEFINING PATENT ELIGIBILITY 
OF NUCLEOTIDES 
Nucleotide technologies present a difficult case for patent 
eligibility because of the close relationship between biotechnol-
ogy and the natural properties of DNA.79 The Supreme Court 
ruled on the patent eligibility of nucleotide sequences generally 
in Association for Molecular Pathology v. Myriad Genetics.80 
Myriad determined the chromosomal coordinates for the BRCA1 
and BRCA2, which are commonly implicated in breast and ovar-
ian cancer.81 At issue in Myriad were nine claims from three pa-
tents, though the holding focused in particular on four claims 
directed to different DNA formulations: the full-length BRCA1 
gene sequence, the BRCA1 complementary DNA (cDNA) se-
quence,82 any DNA molecule of at least fifteen nucleotides hav-
ing the identical sequence to any portion of the full-length 
BRCA1 sequence, and any DNA molecule of at least fifteen nu-
cleotides having the identical sequence to any portion of the 
BRCA1 cDNA sequence.83 In effect, Myriad’s patents gave it “the 
exclusive right to isolate and individual’s BRCA1 and BRCA2 
genes (or any strand of 15 or more nucleotides within the genes) 
 
 77. Vanda Pharm. Inc. v. W.-Ward Pharm. Int’l Ltd., 887 F.3d 1117, 1121, 
1136 (Fed. Cir. 2018), petition for cert. filed, 87 U.S.LW. 3279 (U.S. Jan. 17, 
2019) (No. 18-817). 
 78. Id. 
 79. Cf. Diane Gershon, Recombinant DNA Technology, 348 NATURE 92, 92–
93 (1990) (describing the commercialization of recombinant DNA technology, 
which exploits natural properties of DNA, including hybridization, polymeriza-
tion, mRNA structure, and restriction enzyme-based DNA modification). 
 80. Ass’n for Molecular Pathology v. Myriad Genetics, Inc., 569 U.S. 576, 
580 (2013) (“This case . . . requires us to resolve whether a naturally occurring 
segment of deoxyribonucleic acid (DNA) is patent eligible under 35 U.S.C. § 101 
by virtue of its isolation from the rest of the human genome.”). 
 81. See id. at 582–83 (“Mutations in these genes can dramatically increase 
an individual’s risk of developing breast and ovarian cancer.”). 
 82. A “cDNA” molecule is created by using an mRNA molecule as a tem-
plate to synthesize DNA “complementary” in sequence to the mRNA molecule. 
See id. at 582 (describing a laboratory method by which DNA can be created 
synthetically from “an mRNA molecule”). 
 83. See id. at 584 (describing each claim at issue). 
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. . . [and] to synthetically create BRCA cDNA.”84 Because “isola-
tion is necessary to conduct genetic testing,” Myriad’s patents 
also gave it a monopoly over diagnostic applications of the 
BRCA1 and BRCA2 genes.85 The case arose on an action for de-
claratory judgement seeking a declaration that Myriad’s patents 
were directed to ineligible subject matter and therefore invalid 
under 35 U.S.C. § 101.86 
The Court found that Myriad’s claims to full-length gene se-
quences were invalid under 35 U.S.C. § 101 because they repre-
sent naturally occurring DNA sequences and that neither dis-
covering the chromosomal location of a gene nor “separating the 
gene from its surrounding genetic material . . . is an act of inven-
tion.”87 However, recognizing that naturally occurring genomic 
DNA sequences contain subsections known as “introns” and “ex-
ons,” the Court ruled that claims for cDNA sequences were pa-
tent-eligible because those sequences contain only exons and 
therefore represent a DNA sequence that is not naturally occur-
ring.88 The Court further recognized that there may be a se-
quence of cDNA that is sufficiently short so that it has an iden-
tical sequence to a genomic DNA sequence, and that such a 
cDNA would not be patent-eligible under 35 U.S.C. § 101.89 Im-
portantly, the Court did not address method claims directed to 
or involving DNA sequences,90 though it did suggest that the 
techniques for isolating DNA described in Myriad’s patents were 
“well understood, widely used, and fairly uniform,”91 suggesting 
that they would likely be patent ineligible. Further, the Court 
did not directly address the patent eligibility of a DNA molecule 
having an unusual or non-natural composition, as Myriad’s 
 
 84. Id. at 585. 
 85. Id. 
 86. Id. at 589 n.3. 
 87. Id. at 592. 
 88. Id. at 594–95 (“cDNA retains the naturally occurring exons of DNA, but 
it is distinct from the DNA from which it was derived. As a result, cDNA is not 
a ‘product of nature’ and is patent eligible under § 101 . . . .”). 
 89. Id. at 595 (“[A cDNA sequence is patent eligible] except insofar as very 
short series of DNA may have no intervening introns to remove when creating 
cDNA.”). 
 90. Id. (“[T]here are no method claims before this Court.”). 
 91. Id. at 595–96 (internal quotation marks omitted) (quoting Ass’n for Mo-
lecular Pathology v. U.S. Pat. & Trademark Office, 702 F. Supp. 2d 181, 202–
03 (S.D.N.Y. 2010)). 
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claims were primarily directed to nucleotide sequences rather 
than chemical compositions.92 
In University of Utah Research Foundation v. Ambry Genet-
ics, a case related to Myriad Genetics, Myriad filed suit against 
Ambry Genetics for infringing three of its patents, including two 
of the patents at issue in Myriad.93 Myriad alleged that Ambry 
sold kits to detect susceptibility to certain breast and ovarian 
cancers—Ambry counterclaimed that the relevant patents were 
invalid under 35 U.S.C. § 101.94 Specifically, Ambry alleged that 
four composition of matter claims directed to DNA primers 
(“short, synthetic, single-stranded DNA molecules” that are com-
plementary to a specific nucleotide sequence95 and are capable 
of initiating DNA replication)96 and two method claims “in-
volv[ing] comparisons between the wild-type BRCA sequences 
with the patient’s BRCA sequences” were invalid.97 
Citing Myriad’s proposition that claims to DNA sequences—
including those that do not occur naturally, like the synthetic 
DNA primers claimed in Myriad’s patents—as short as 15 nucle-
otides (the length of the primers in Myriad’s claims) could be 
held invalid if they have identical sequences to DNA molecules 
found in nature, the Federal Circuit held Myriad’s claims to 
DNA primers invalid under 35 U.S.C. § 101. Despite the fact that 
the primers themselves were not naturally occurring and, in 
fact, no DNA molecule having a single-stranded structure natu-
rally occurs within the human body, the Court held the claims 
invalid because they had an identical sequence to a portion of 
naturally occurring DNA98 and therefore did not have a “unique 
structure.”99 Moreover, the Federal Circuit found the fact that 
 
 92. Id. at 593 (“[Myriad’s] claim is concerned primarily with the infor-
mation contained in the genetic sequence, not with the specific chemical compo-
sition of a particular molecule.”). 
 93. Univ. of Utah Research Found. v. Ambry Genetics, 774 F.3d 755, 757 
(Fed. Cir. 2014). Ambry Genetics was decided by the Federal Circuit one year 
after the Supreme Court’s ruling in Myriad. 
 94. Id. at 758. 
 95. Id. (internal quotation marks omitted) (citation omitted). 
 96. Primers, NATURE EDUC.: SCITABLE, https://www.nature.com/scita-
ble/definition/primer-305 (last visited Nov. 12, 2018). 
 97. Ambry, 774 F.3d at 759. 
 98. Id. at 760. 
 99. Id. at 761 (emphasis added). The Federal Circuit’s holding is unclear as 
to whether a nucleotide sequence is generally its “structure” for the purposes of 
35 U.S.C. § 101 analysis or whether that is the case only for DNA primers. See 
discussion infra Section III.B. (“[T]he Federal Circuit has used a nebulous, and 
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DNA primers are able to serve as a starting material for DNA 
polymerization irrelevant, holding that the primers did not “per-
form a significantly new function”100 despite the fact that natu-
rally occurring DNA replication utilizes RNA primers rather 
than DNA primers.101 Instead, the Federal Circuit identified the 
function of DNA primers as the ability of “complementary nucle-
otide sequences [to] bind to each other,” which is an “innate abil-
ity of DNA.”102 Further, because the two method claims at issue 
involved “comparison steps,” the Federal Circuit found that the 
claims recited abstract ideas and subjected them to analysis un-
der Alice.103 Under the second step of Alice, the Court found that 
the “non-patent-ineligible elements” of the claims were “well-un-
derstood, routine, and conventional,” and therefore did not 
“make the claims as a whole patent-eligible.”104 
E. A RECENT CASE ELABORATES ON NUCLEOTIDE PATENT 
ELIGIBILITY 
A recent Federal Circuit case, Roche Molecular Systems, Inc. 
v. CEPHEID, offers additional guidance on the patent eligibility 
of nucleotide sequences.105 Primarily at issue in Roche were two 
families of claims in a patent related to the detection rpoB, a 
gene associated with drug-resistant strains of the pathogen My-
cobacterium tuberculosis.106 The first claim family was directed 
to a primer for use with polymerase chain reaction (PCR) tech-
 
perhaps counter-intuitive, definition of ‘nucleotide structure.’”); cf. Ambry, 774 
F.3d at 761 (“Primers do not have [a unique] structure and are patent ineligi-
ble.”). 
 100. Ambry, 774 F.3d at 761. 
 101. See Appellants’ Opening Brief at 7, Ambry, 774 F.3d 755 (2014) (Nos. 
14-1361, 14-1366) (“There are no short, single strands of DNA with a free 3′-OH 
group in nature that can serve as primers. In natural DNA replication, RNA 
primers are used as the starting material.”). 
 102. Ambry, 774 F.3d at 761. 
 103. Id. at 764. 
 104. Id. 
 105. Roche Molecular Sys., Inc. v. CEPHEID, 905 F.3d 1363, 1366 (Fed. Cir. 
2018) (“[T]he [patent at issue] involves subjecting DNA extracted from a biolog-
ical sample taken from a patient (e.g., a tissue or fluid sample) to amplification 
by polymerase chain reaction (‘PCR’) using a short, single-stranded nucleotide 
sequence (a ‘primer’).”). 
 106. See id. (“The [patent at issue] provides two types of claims: (1) compo-
sition-of-matter claims [of which there is one independent claim] . . . and (2) 
process claims for methods [of which there is one independent claim] . . . .”). 
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niques capable of “hybridizing” to rpoB and having “14–50 nu-
cleotides.”107 The second claim family was directed to a process 
for “amplifying” rpoB using a “plurality of primers” capable of 
hybridizing to a “site comprising at least one position-specific 
[M. tuberculosis] signature nucleotide” and “detecting” the am-
plified gene product.108 
In a panel decision, a two-judge majority held that Ambry 
dictated that the primers were patent ineligible because they 
contained an identical sequence to naturally occurring DNA.109 
The majority opinion rejected Roche’s arguments that the pri-
mers were chemically and structurally distinct from any natu-
rally occurring DNA molecule, relying on the Ambry court’s re-
jection of similar arguments.110 Roche further argued that the 
structure of its primers was more distinct from their relevant M. 
tuberculosis DNA counterparts than was the case with the pri-
mer/gene pairs at issue in Ambry because M. tuberculosis has a 
circular chromosome that lacks the 3’ end present in the primer 
sequences. The majority opinion also rejected this argument, 111 
as well as Roche’s contentions about the “specificity” of the pri-
mers described in the patent.112 Therefore, the majority found 
that Roche’s primer claims were patent ineligible.113 
As to the method claims at issue, the majority found that 
the claims were directed to “a relationship between the . . . nat-
urally occurring position-specific signature nucleotides and the 
presence of [M. tuberculosis] in a sample.”114 Applying Alice, the 
majority looked to the rest of the claim to see if there was an 
“inventive concept that transforms [the claim] into patent-eligi-
ble subject matter.”115 It found that the “amplification” step was 
 
 107. Id. at 1367 (citing U.S. Patent No. 5,643,723 col. 28 ll. 14–31 (filed May 
26, 1994)). 
 108. Id. (citing U.S. Patent No. 5,643,723 col. 25 l. 57–col. 27 l. 6 (filed May 
26, 1994)). 
 109. Id. at 1371 (“[Roche’s primers] are indistinguishable from their corre-
sponding nucleotide sequences on the naturally occurring DNA, and . . . there-
fore, are patent-ineligible within the meaning of § 101.”). 
 110. Id. at 1369–70 (citing Ambry, 774 F.3d at 761). 
 111. Id. at 1370. 
 112. Id. 
 113. Id. at 1371. 
 114. Id. 
 115. Id. at 1372. 
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“‘routine’ when the patent application was filed”116 and that the 
“detecting” step was “devoid of an inventive concept because it 
involves a simple mental determination.”117 The majority fur-
ther distinguished Roche’s method from a method for treating a 
disease with a new drug because Roche’s claims relied on the 
ability of their primers to hybridize to complementary nucleotide 
sequences.118 The opinion classified the hybridization of comple-
mentary nucleotides as a patent-ineligible “law of nature.”119 
However, the majority stated in a footnote that they “express[ed] 
no opinion on the subject matter eligibility of method claims that 
exploit DNA or RNA for drug-like new applications.”120 
Writing separately in a concurring opinion, Judge O’Malley 
agreed that Ambry required that the claim be held invalid, but 
felt that the court should “revisit [the] holding in [Ambry] at 
least with respect to the primer claims.”121 O’Malley argued that 
the validity of claims directed to DNA primer was not the ques-
tion at issue in Ambry—rather, she characterized the question 
before the Ambry court as whether the district court had abused 
its discretion in denying a preliminary injunction.122 Moreover, 
she suggested that the Federal Circuit’s decision in Ambry suf-
fered from a lack of record evidence and that Roche’s DNA pri-
mer may have a unique, non-naturally occurring structure, and 
further “challenge[d] the conclusion that th[e] entire class of 
[DNA primer] molecules is ineligible under § 101.”123 O’Malley 
distinguished the structure of DNA primers from their nucleo-
tide sequence and therefore challenged the court’s determina-
tion of nucleotide structure based on only nucleotide sequence.124 
Further, O’Malley found unclear how primers “are structurally 
 
 116. Id. (quoting Roche Molecular Sys., Inc. v. CEPHEID, No.14-CV-03228-
EDL, 2017 WL 6311568, at *15 (N.D. Cal. 2017)). 
 117. Id. 
 118. Id. at 1373. 
 119. Id. 
 120. Id. at 1373 n.6. 
 121. Id. at 1375 (O’Malley, J., concurring). 
 122. Id. (O’Malley, J., concurring). 
 123. Id. at 1377 (O’Malley, J., concurring). 
 124. Id. (O’Malley, J., concurring) (“[A] finding that the two [primers] have 
identical sequences does not entirely resolve the question of whether they 
are structurally identical because structure is not defined solely by nucleotide 
sequence.”). 
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identical to the ends of DNA strands found in nature.”125 Like-
wise, O’Malley found that the record before the court also sug-
gested that the primers at issue have a unique function as com-
pared to naturally occurring DNA.126 Ultimately, she found that 
Roche had submitted “evidence . . . that, at the very least, raises 
genuine issues of material fact as to whether there exists any-
thing in nature that both has the structure and performs the 
function of the claimed primers.”127 
F. THERE ARE NO EXISTING INTERPRETATIONS OF § 101 AS 
APPLIED TO SIRNA 
There are virtually no adjudications of the patent eligibility 
of claims directed to siRNA technologies.128 As discussed in Sec-
tion I.E. of this note,129 the Federal Circuit has expressly de-
clined to comment on the patent eligibility of claims directed to 
RNA therapeutics.130 The Patent Trial and Appeal Board 
(PTAB) found in Ex parte Khvorova that “the ability of siRNA 
sequences to silence genes is ‘directed to naturally occurring phe-
nomena.’”131 However, the patent at issue in Khvorova was spe-
cifically directed to an algorithm for “determining . . . whether a 
particular siRNA sequence will result in gene silencing.”132 To 
that extent, the PTAB did not decide on the patent eligibility of 
RNA therapeutics. The PTAB ultimately found that the claim at 
issue “does not recite a specific algorithm . . . [and] preempts any 
algorithm for designing siRNA sequences,” and therefore was 
patent ineligible under 35 U.S.C. § 101.133 
 
 125. Id. (O’Malley, J., concurring) (quoting Ambry, 774 F.3d at 760) (internal 
quotation marks omitted). 
 126. Id. at 1380 (O’Malley, J., concurring). 
 127. Id. at 1381 (O’Malley, J., concurring). 
 128. See Esmond & Chung, supra note 12, at 26–27 (describing litigation of 
siRNA as dealing with inventorship, patent malpractice, and trade secret dis-
putes). 
 129. See discussion supra Section I.E. 
 130. Roche Molecular Sys., 905 F.3d at 1373 n.6. 
 131. Ex parte Khvorova, No. 2012-010359, 2015 WL 4267897, at *4 (P.T.A.B. 
July 10, 2015) (quoting Ariosa Diagnostics, Inc. v. Sequenom, Inc., 788 F.3d 
1371, 1376 (Fed. Cir. 2015)). 
 132. Id. at *3 (citing U.S. Pub. No. 10/940,892, claim 85 (filed Nov. 17, 2005)). 
 133. Id. at *5. 
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G. THE PATENT LANDSCAPE OF SIRNA TECHNOLOGIES 
A search of the Patent Full-Text Database for claims that 
contain the term “siRNA” returns over 2,200 patents.134 Further, 
a survey of siRNA patent families by Robert W. Esmond and 
Alex Kwan-Ho Chung identified three main patent families of 
siRNA technologies: the “Carnegie” patents, broadly directed to 
double-stranded RNA (dsRNA) inhibition, the “Tuschl I” pa-
tents, directed to short (twenty-one to twenty-three nucleotide) 
dsRNAs and methods of inhibition using short dsRNAs, and the 
“Tuschl II” patents, claiming dsRNAs with nineteen to twenty-
five nucleotides and 3’ overhangs as well as a method of prepar-
ing such dsRNAs.135 The Carnegie patents expired at the end of 
2018, and therefore are not likely to prevent “generic” manufac-
ture of siRNA therapeutics.136 However, both the Tuschl patent 
families are set to expire in 2021, and therefore have the poten-
tial to “block companies from marketing [their own] siRNA ther-
apeutics.”137 Esmond and Chung postulate that infringement lit-
igation or inter partes review (IPR) may occur with regard to 
these patents if a claimed siRNA therapeutic receives FDA ap-
proval prior to the expiry of their patent term.138 However, if no 
therapeutic receives FDA approval by that time, any litigation 
or IPR will likely concern a patent having a more specific claim 
scope.139 As of September 15, 2017, there were 20 clinical trials 
of miRNA- and siRNA-based therapeutics.140 More recently, the 
FDA has for the first time granted marketing approval to an 
siRNA-based therapy,141 indicating that there may soon be liti-
gation concerning these foundational siRNA patents.142 RNA-
 
 134. Patent Full-Text Database, U.S. PAT. TRADEMARK OFF., 
http://patft.uspto.gov/ (last visited Nov. 19, 2018) (follow “Advanced Search” hy-
perlink; then search for “ALCM/siRNA”). 
 135. Esmond & Chung, supra note 12, at 17–18. 
 136. Id. at 18. 
 137. Id. 
 138. See id. at 27 (describing the likelihood of litigation as compared to IPR 
of a patented technology that achieves FDA approval prior to the expiry of its 
relevant patent term). 
 139. Cf. id. (“After 2021, litigation concerning [the Carnegie, Tuschl I, and 
Tuschl II] siRNA and nanoparticle patents will be unlikely, as no company will 
have a dominating position.”). 
 140. Chakraborty et al., supra note 4, at 132. 
 141. RNA-Based Therapy, supra note 4. 
 142. But Cf. Esmond & Chung, supra note 12, at 27 (“After 2021, litigation 
concerning siRNA and nanoparticle patents will be unlikely, as no company will 
have a dominating position.”). 
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based therapeutics more generally are expected to have signifi-
cant economic growth within the next decade and at least one 
organization has suggested that RNAi technologies could repre-
sent a $1.81 billion market by 2025.143 
H. PATENT PROTECTION ENCOURAGES INVESTMENT 
Because of the high cost of both developing and performing 
clinical trials on a new drug, “pharmaceutical companies are 
rarely willing to develop drugs without patent protection.”144 A 
developer of a new drug may spend “hundreds of millions of dol-
lars on clinical trials” while the drugs manufactured by a generic 
competitor are “exempted from [safety and efficacy standards] 
and enter the market at minimal cost[,]”145 making patent pro-
tection arguably more important to pharmaceutical developers 
than other industries.146 To this end, pharmaceutical manufac-
turers “regularly screen their drugs in R&D and discard ones 
with weak patent protection.”147 Like conventional therapeutics, 
siRNA-based drugs also require FDA approval,148 and will there-
fore encounter similar financial hurdles as conventional thera-
peutics. Some commentators have expressed fears that recent 
interpretations of 35 U.S.C. § 101 (including Mayo and Myriad) 
could “curtail further research and investment in areas broader” 
than the subject matter covered by the judicial exceptions.149 
Though at least one decision from the Federal Circuit seems to 
have utilized economic investment as justification that a tech-
 
 143. See Antisense & RNAi Therapeutics Market Size Worth $1.81 Billion By 
2025, GRAND VIEW RESEARCH (Mar. 2018), https://www.grandviewre-
search.com/press-release/antisense-rnai-therapeutics-market [hereinafter An-
tisense & RNAi]. 
 144. Benjamin N. Roin, Unpatentable Drugs and the Standards of Patenta-
bility, 87 TEX. L. REV. 503, 505 (2009). 
 145. Id. 
 146. Cf. id. (“At a time when many scholars believe that patents often do 
more harm than good, the pharmaceutical industry is widely thought to show-
case the benefits of patents.”). 
 147. Id. 
 148. See RNA-Based Therapy, supra note 4 (announcing the first FDA-ap-
proved siRNA-based drug). 
 149. See, e.g., Robert L. Stoll, Are Patent Decisions Strangling Our Econ-
omy?, HILL (May 13, 2016, 11:30 AM), https://thehill.com/blogs/pundits-
blog/technology/279830-are-patent-decisions-strangling-our-economy (“This 
spate of decisions is clouding the validity of patents in everything from diagnos-
tic methods to personalized medicine to business methods and gaming.”). 
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nology is not “conventional, routine, and well-understood” at Al-
ice step two,150 “labor” or “investment” in developing a technol-
ogy is generally insufficient to overcome challenges under 35 
U.S.C. § 101.151 
II. ANALYSIS 
The potential 35 U.S.C. § 101 eligibility of siRNA patent 
claims will be discussed by applying Supreme Court and Federal 
Circuit precedent on DNA patents. In particular, siRNA will be 
analyzed because of its utility in medical applications.152 Since 
the vast majority of siRNA patents are claimed as compositions 
of matter or processes,153 each of these statutory classes will be 
addressed separately. Moreover, the major patent families iden-
tified by Esmond and Chung will be utilized as relevant exam-
ples of siRNA claim formulation.154 
A. SIRNA IS LIKELY INELIGIBLE AS A COMPOSITION OF MATTER 
Claims to siRNA formulated as a composition of matter may 
likely be patent-ineligible under the rulings in Myriad155 and 
 
 150. Cf. Exergen Corp. v. Kaz USA, Inc., 725 F. App’x 959, 966 (Fed. Cir. 
2018) (“Following years and millions of dollars of testing and development, the 
inventor determined for the first time the coefficient representing the relation-
ship between temporal-arterial temperature and core body temperature and in-
corporated that discovery into an unconventional method of temperature meas-
urement.”) (emphasis added). 
 151. See, e.g., Ass’n for Molecular Pathology v. Myriad Genetics, Inc., 569 
U.S. 576, 577 (2013) (“[E]xtensive effort alone is insufficient to satisfy § 101’s 
demands.”). 
 152. See Lam et al., supra note 45, at 255 (describing siRNAs as “extremely 
useful for targeting single gene disorders” and as having been favored by re-
searchers as potential therapeutics due to the uncertainty surrounding miRNA 
“mechanism of action and specificity”). 
 153. See, e.g., U.S. Patent No. 8,552,171 (filed Oct. 10, 2004) (claiming siRNA 
as a composition of matter); see, e.g., U.S. Patent No. 6,506,559 (filed Dec. 18, 
1998) (claiming siRNA as a process). See generally Esmond & Chung, supra note 
12, at 17–18 (detailing three fundamental families of siRNA patents as claiming 
compositions of matter or processes). 
 154. See Esmond & Chung, supra note 12, at 17–18. 
 155. Ass’n for Molecular Pathology v. Myriad Genetics, Inc., 569 U.S. 576 
(2013). 
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Ambry.156 Generally, siRNAs function by complementary inter-
action with a target mRNA.157 In Myriad, the Court held that 
cDNA was patent-eligible insofar as it does not contain intron 
sequences that would otherwise be present in the corresponding 
genomic DNA sequence.158 The Federal Circuit restated this 
holding in Ambry as generally prohibiting composition of matter 
claims directed to nucleotides sequences having a utility based 
on complementary binding.159 Under the holding in Myriad, pa-
tents directed to siRNA molecules would likely not be patent-
eligible if they claimed sequences identical to a naturally occur-
ring mRNA molecule.160 Patents that claim siRNA that is “per-
fectly complementary to an mRNA” 161 are likely to be found pa-
tent ineligible in view of Myriad because there are no “intron 
sequences” to remove when designing siRNA molecules. Since 
siRNA must have perfect identity with a target mRNA in order 
to induce a silencing effect,162 this is likely to be problematic for 
claims to siRNA as a composition of matter. Neither the thera-
peutic function of the siRNA163 nor the specificity of an siRNA to 
any particular mRNA164 is likely to improve the patent eligibility 
of a perfectly complementary siRNA sequence in view of Ambry’s 
 
 156. Univ. of Utah Research Found. v. Ambry Genetics, 774 F.3d 775 (Fed. 
Cir. 2014). 
 157. See Pratt & MacRae, supra note 3, at 17899 (“[T]he [miRNA or siRNA] 
guide strand form[s] a Watson-Crick-paired, A-form double helix with a com-
plementary region of the target RNA.”). 
 158. Myriad, 569 U.S. at 595. 
 159. Ambry, 774 F.3d at 761. 
 160. Cf. Myriad, 569 U.S. at 595 (“As a result, cDNA is not a ‘product of 
nature’ and is patent eligible under § 101, except insofar as very short series of 
DNA may have no intervening introns to remove when creating cDNA.”). 
 161. See, e.g., U.S. Patent No. 8,552,171 (filed Oct. 10, 2004) (claiming siRNA 
that is “perfectly complementary to an mRNA.”). 
 162. See Lam et al., supra note 45, at 253 (“To elicit RNAi, the siRNA must 
be fully complementary to its target mRNA.”). 
 163. See Ambry, 774 F.3d at 760–61 (holding that the primary function for 
the purposes of patent eligibility of a complementary nucleotide is the ability of 
one complementary nucleotide sequence to bind to another even where the nu-
cleotide sequence performs other functions). 
 164. See Roche Molecular Sys., Inc. v. CEPHEID, 905 F.3d 1363, 1370 (Fed. 
Cir. 2018) (holding that nucleotide sequences that are bind to natural sequences 
with high specificity are patent ineligible if they have an identical sequence to 
a naturally occurring sequence). 
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prohibition on the patenting of nucleotides having a utility based 
on complementary binding.165 
However, many siRNA sequences contain additional nucle-
otides or other alterations that could be a “chemical modifica-
tion” sufficient to render the sequence patent-eligible.166 For ex-
ample, the Tuschl II family of patents claim siRNA therapeutics 
that contain a 3’ overhang of one to three nucleotides.167 The 
Federal Circuit has indicated that mutations can render other-
wise ineligible sequences patent-eligible.168 Though the Federal 
Circuit has not provided guidance as to how many mutations are 
required for patent eligibility of such a sequence, its emphasis 
on disallowing DNA having “identical nucleotide sequences as 
naturally occurring DNA” suggests that even a single altered nu-
cleotide may be sufficient to make a sequence patent-eligible.169 
Adding nucleotides should be treated by the courts as equivalent 
to mutating nucleotides because either process makes the rele-
vant nucleotide sequence “different from those found in na-
ture.”170 Likewise, claims to siRNA that contain non-naturally 
occurring nucleotides171 may be patent-eligible because natu-
rally occurring sequences inherently do not contain non-natu-
rally occurring nucleotides. However, would-be patentees cannot 
simply add “conventional” 3’ nucleotide overhangs172 in order to 
bring their claims into patent eligibility,173 likely limiting this 
strategy of patent claiming to overhangs or modifications that 
 
 165. See Ambry, 774 F.3d at 761 (holding that the ability of DNA primers to 
selectively bind a target DNA sequence is not a “significantly new function”). 
 166. See Roche Molecular Sys., 905 F.3d at 1370 (“[A] primer having an iden-
tical nucleotide sequence to naturally occurring DNA without further chemical 
modification is a natural phenomenon.”). 
 167. See, e.g., U.S. Patent No. 8,362,231 (filed Mar. 24, 2011) (claiming an 
RNA molecule wherein “at least one RNA strand forms a single-stranded 3’-
overhang from 1 to 3 nucleotides”). 
 168. See Roche Molecular Sys., 905 F.3d at 1369 (“Nothing in the ’723 patent 
suggests that the Roche inventors introduced any mutations that would have 
made the primers’ nucleotide sequences different from those found in nature.”). 
 169. See, e.g., id. at 1370 n.5 (“We do not address the subject matter eligibil-
ity of primers that have been altered.”). 
 170. Id. at 1369. 
 171. See, e.g., U.S. Patent No. 8,552,171 (filed Oct. 10, 2004). 
 172. See, e.g., Lam et al., supra note 45, at 255 (citing Walton et al., supra 
note 57, at 4807) (describing conventional siRNA overhangs). 
 173. See Mayo Collaborative Servs. v. Prometheus Labs., Inc., 566 U.S. 66, 
at 79 (2012) (holding that “well-understood, routine, conventional activity pre-
viously engaged in by scientists in the field” is not sufficient to bring patent 
ineligible subject matter into § 101 eligibility). 
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themselves are novel.174 Because the common overhangs of 
siRNA are conventionally limited to a small pool of sequences,175 
they are likely insufficient to improve the patent eligibility of 
siRNA composition of matter claims.176 
Further, any argument that claims to explicitly double-
stranded siRNA should be patent-eligible for the reason that a 
complementary mRNA is single-stranded as it exists in nature 
is likely to be rejected. Because the Federal Circuit held in Am-
bry that “separating DNA from its surrounding genetic material 
[is] not an act of invention,”177 the argument would draw 
strength from the fact that the second strand of a double-
stranded siRNA does not serve to “separate” it from its sur-
rounding environment. Rather, the second strand can be de-
scribed as “added” over the single-strand present in the comple-
mentary mRNA.178 However, because the Federal Circuit has 
indicated that nucleotides deriving utility from complementary 
binding are generally patent ineligible, an argument that an 
RNA is patent-eligible by reason of a two-stranded, complemen-
tary structure is likely be to rejected (even if that structure does 
not exist in nature) because complementarity is “[o]ne of the pri-
mary functions of [nucleotide] structure in nature.”179 
B. SIRNA METHOD CLAIMS HAVE LIMITED PATENT ELIGIBILITY 
Only the Federal Circuit has provided guidance on patent 
eligibility of methods involving nucleotide sequences,180 doing so 
in Ambry and Roche.181 However, Ambry dealt with method 
 
 174. Cf. id. 
 175. See, e.g., Lam et al., supra note 45, at 255 (citing Walton et al., supra 
note 57, at 4807) (“A conventional siRNA consists of 19–21 nucleotides with two 
nucleotide overhangs at the 3′ end, usually TT and UU, which are important for 
recognition by the RNAi machinery.”). 
 176. Cf. Mayo, 566 U.S. at 79 (holding that “conventional activity previously 
engaged in by scientists in the field” is insufficient to cure patent ineligibility). 
 177. Id. (citing Ass’n for Molecular Pathology v. Myriad Genetics, Inc., 569 
U.S. 576, 591) (internal quotation marks omitted). 
 178. See, e.g., Lam et al., supra note 45, at 252. 
 179. Univ. of Utah Research Found. v. Ambry Genetics, 774 F.3d 775, 761 
(Fed. Cir. 2014). 
 180. Id. at 761 (citing Ass’n for Molecular Pathology v. Myriad Genetics, Inc., 
569 U.S. 576, 595) (“While we addressed some of the method claims of the ‘441 
patent in our Myriad decision, the Supreme Court did not address any method 
claims.”). 
 181. Id. at 764; Roche Molecular Sys., Inc. v. CEPHEID, 905 F.3d 1363, 1366 
(Fed. Cir. 2018). 
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claims directed to the detection of mutations following routine 
DNA amplification or probe hybridization.182 Likewise, the 
method claims contested in Roche were directed to a method of 
detecting a gene product based on amplification by polymerase 
chain reaction (PCR).183 
Of the major siRNA patent families identified by Esmond 
and Chung as examples, only U.S. 8,420,391 (the ‘391 patent) of 
the Tuschl I claims a method for using siRNA sequences.184 The 
‘391 patent recites a method for “introducing” siRNA into cells, 
“maintaining” the resulting cells under conditions suitable for 
RNA interference, and “thereby producing” a knockdown effect, 
reducing the expression of a particular gene.185 Unlike the 
claims contested in Ambry and Roche, these claims do not recite 
the abstract idea of “comparing,”186 but nonetheless likely recite 
a patent-ineligible natural phenomena. The steps recited by the 
‘391 patent are similar to those recited by the patent at issue in 
Mayo—that is, the knockdown effect recited by the ‘391 patent 
is produced by interaction of the siRNA with the RNAi pathway, 
which exists in nature.187 To that extent, “producing” a knock-
down effect by using that natural phenomena is also patent-in-
eligible subject matter.188 Though there is no caselaw from arti-
cle III courts on point, the PTAB has ruled consistently with this 
analysis.189 The question then is whether the remainder of the 
 
 182. Ambry, 774 F.3d at 764. 
 183. Roche Molecular Sys., 905 F.3d at 1366. 
 184. See, e.g., U.S. Patent No. 8,420,391 (filed Nov. 24, 2011); see also Es-
mond & Chung, supra note 12, at 17–18. 
 185. U.S. Patent No. 8,420,391 (filed Nov. 24, 2011) (reciting four independ-
ent claims containing only “introducing,” “maintaining,” and “producing” steps). 
 186. Ambry, 774 F.3d at 764; Roche Molecular Sys., 905 F.3d at 1369. 
 187. Cf. Mayo Collaborative Servs. v. Prometheus Labs., Inc., 566 U.S. 66, 
77 (2012) (“Prometheus’ patents set forth laws of nature—namely, relationships 
between concentrations of certain metabolites in the blood and the likelihood 
that a dosage of a thiopurine drug will prove ineffective or cause harm.”). See 
generally RNA Interference (RNAi), supra note 1. 
 188. Cf. Mayo, 566 U.S. at 77 (“If a law of nature is not patentable, then 
neither is a process reciting a law of nature, unless that process has additional 
features that provide practical assurance that the process is more than a draft-
ing effort designed to monopolize the law of nature itself.”). 
 189. See ex parte Khvorova, No. 2012-010359, 2015 WL 4267897, at *4 
(P.T.A.B. July 10, 2015) (quoting Ariosa Diagnostics, Inc. v. Sequenom, Inc., 788 
F.3d 1371, 1376 (Fed. Cir. 2015)). 
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claims “add ‘enough’ to make the claims as a whole patent-eligi-
ble.”190 The other steps recited by the ‘391 patent are “introduc-
ing” and “maintaining.”191 It is likely that these steps do not add 
enough to make the claims as a whole patent-eligible. 
Looking to Ambry, “techniques that a scientist would have 
thought of” are insufficient to cure patent-ineligible subject mat-
ter.192 Likewise, Mayo held that even a combination of steps is 
ineligible where “the combination amounts to nothing signifi-
cantly more than an instruction to [the relevant audience] to ap-
ply the applicable laws [of nature].”193 The ‘391 patent appears 
to fail both formulations. Expert testimony notwithstanding, it 
is obvious that a scientist would have thought of “introducing” 
RNAi-capable RNA and “maintaining” cells in conditions suita-
ble for RNAi in order to produce an RNAi-mediated knock-
down.194 Likewise, these steps are effectively an instruction on 
how to apply the law of nature, because producing an RNAi-me-
diated knockdown requires RNAi-capable RNA and “conditions 
under which RNA . . . interference occurs.”195 Therefore, siRNA 
patents should avoid the formulation used by the ‘391 patent in 
order to avoid invalidity for failing to recite patent-eligible sub-
ject matter. Further, Ambry expressly forecloses the patenting 
of a DNA sequence based on its ability to “hybridize,” meaning a 
claiming strategy focused on the initial siRNA/mRNA hybridiza-
tion event is just as likely to fail for failing to recite patent-eligi-
ble subject matter as claims focused on the later knockdown 
event.196 
Two patents from the Tuschl II family offer a different ap-
proach to siRNA method claims by reciting methods of producing 
siRNA molecules.197 Both U.S. Patent No. 7,056,704 and U.S. 
Patent No. 7,078,196 recite “synthesizing” two RNA strands and 
 
 190. Ambry, 774 F.3d at 764. 
 191. U.S. Patent No. 8,420,391 (filed Nov. 24, 2011). 
 192. Ambry, 774 F.3d at 764. 
 193. Mayo, 566 U.S. at 79. 
 194. Cf. Lam et al., supra note 45, at 255–56 (summarizing existing best-
practices for RNA interfering techniques). 
 195. Compare id., with U.S. Patent No. 8,420,391 (filed Nov. 24, 2011). 
 196. See Ambry, 774 F.3d at 761 (finding that the ability of DNA primers to 
hybridize to other DNA strands is simply a manifestation of “the innate ability 
of DNA to bind to itself”). 
 197. U.S. Patent No. 7,056,704 (filed Dec. 23, 2004); U.S. Patent No. 
7,078,196 (filed Nov. 11, 2004); see Esmond & Chung, supra note 12, at 17–18. 
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“combining” the synthesized strands.198 Insofar as the claims 
cannot be construed to cover unpatentable siRNA sequences (as 
discussed in section II.A of this note),199 this type of method 
claim may be patent-eligible. However, because synthesizing 
and combining are “routine” and “conventional,” this type of 
claiming strategy likely does not function as a workaround to the 
validity of a corresponding composition of matter claim, 200 and 
may therefore have extremely limited practical utility to patent 
drafters. 
C. CLAIMING A METHOD OF TREATMENT REMAINS AN OPTION TO 
OVERCOME § 101 HURDLES 
Instead of patenting methods of administering siRNA to 
trigger the RNAi biological pathway, would-be siRNA patentees 
might be able to overcome § 101 challenges by following the pa-
tent held subject-matter eligible in Vanda and formulating their 
claims as a method of treating a disease or disorder.201 Though 
the treatment in that case utilized a small molecule, the court’s 
holding did not rest on the small molecule’s structure, but rather 
that the patent at issue recited “a novel method of treating a 
disease.” 202 Further, the Vanda court distinguished the patent 
eligibility of a natural law applied to “treating a disease” from 
the same natural law applied to “administering a drug,” holding 
that using a natural law to treat a disease is patent-eligible sub-
ject matter.203 Therefore, the Federal Circuit’s holding in Vanda 
very likely opens up the door for the patenting of methods of 
treating diseases with siRNA, even where the siRNA itself is 
 
 198. U.S. Patent No. 7,056,704 (filed Dec. 23, 2004); U.S. Patent No. 
7,078,196 (filed Nov. 11, 2004). 
 199. See discussion of the patentability of siRNA as a composition of matter 
supra Section II.A. 
 200. See Ambry, 774 F.3d at 760 (“[A]s the district court in the earlier Myr-
iad case and our opinion in Myriad made clear, isolated DNA is routinely syn-
thetically created.”). 
 201. Cf. Vanda Pharm., Inc. v. W.-Ward Pharm. Int’l Ltd., 887 F.3d 1117, 
1136 (Fed. Cir. 2018), petition for cert. filed, 87 U.S.LW. 3279 (Jan. 17, 2019) 
(No. 18-817) (holding a method of treating schizophrenia to be patent-eligible 
subject matter). 
 202. Id. at 1134. 
 203. Id. (citing Mayo Collaborative Servs. v. Prometheus Labs., Inc., 566 
U.S. 66, 74 (2012)) (“Although the representative claim in Mayo recited admin-
istering a thiopurine drug to a patient, the claim as a whole was not directed to 
the application of a drug to treat a particular disease.”). 
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otherwise patent ineligible.204 However, the court’s holding 
seems to indicate that such a method claim would need to iden-
tify both “specific doses” and a “specific disease” to be treated,205 
which may pose a challenge for siRNA researchers trying to pa-
tent their technology without performing clinical studies. A pe-
tition for certiorari has been filed but has not yet been granted, 
potentially subjecting this approach to an opportunity for rever-
sal by the Supreme Court.206 
III. ALTERNATIVE INTERPRETATIONS AND 
LEGISLATIVE SOLUTIONS 
A lack of patent protection could seriously impact future de-
velopment of siRNA therapeutics, which are forecasted to have 
significant market growth in the next few years.207 Part III of 
this note will explore alternative interpretations of 35 U.S.C. § 
101 that may confer patent eligibility onto siRNA therapeutics 
as well as the role that sections of the Patent Act outside of § 101 
can have to constrain overly broad nucleotide patents under a 
more open interpretation of 35 U.S.C. § 101. Further, it will ex-
plore legislative solutions to incentivize siRNA therapeutic de-
velopment through non-patent market protections. 
A. A LACK OF PATENT PROTECTION MAY STIFLE DEVELOPMENT 
OF SIRNA THERAPEUTICS 
Because pharmaceutical firms tend to discard conventional 
drugs with “weak patent protection” during the drug develop-
ment process,208 limiting the range of patents available to siRNA 
therapeutics could significantly impact their development by 
private research organizations. Private research investment is 
likely critical to rapid development and deployment of any ther-
apeutic compound as pharmaceutical firms currently carry out 
 
 204. Cf. id. at 1135 (holding that “treating a disease” is a patent eligible ap-
plication of a natural law). 
 205. See id. at 1136 (“[T]he [patent-eligible] claims here are directed to a 
specific method of treatment for specific patients using a specific compound at 
specific doses to achieve a specific outcome.”). 
 206. See generally id. 
 207. See, e.g., Antisense & RNAi, supra note 143. 
 208. See Roin, supra note 144, at 505. 
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the majority of drug development in the United States.209 As con-
trasted with the diagnostic methods found ineligible in Mayo 
and Roche,210 the development of therapeutic products benefit 
from exclusive licensing.211 Unless an interpretation of Ambry 
that is favorable to siRNA patenting is adopted by the courts212 
or a legislative solution ensuring siRNA therapeutic market ex-
clusivity is adopted by Congress,213 it is likely that the primary 
route to patent protection for these compounds exists using the 
limited “method of treatment” approach as outlined in Section 
II.C.214 
Federal Circuit precedent states that infringement of a 
method patent can occur only where a single party performs all 
steps of the claimed method.215 Thus, only a physician adminis-
tering the siRNA could be liable for direct infringement of claims 
directed to a method of treatment using siRNA.216 Generally, 
physician liability is severely limited by 35 U.S.C. § 287(c), 
 
 209. See generally Henry G. Grabowski et al., The Roles of Patents and Re-
search and Development Incentives in Biopharmaceutical Innovation, 34 
HEALTH AFF. 302, 303 (describing the role of patents in biopharmaceutical in-
novation as “essential”); cf. Ashley J. Stevens et al., The Role of Public-Sector 
Research in the Discovery of Drugs and Vaccines, 364 NEW ENG. J. MED. 535, 
539–40 (2011) (finding that only 13.6%–21.1% of new drug applications origi-
nated from public sector research institutes). 
 210. Mayo Collaborative Servs. v. Prometheus Labs. Inc., 566 U.S. 66, 87–
88 (2012) (finding a diagnostic test based on a metabolite level to be a patent-
ineligible law of nature); Roche Molecular Sys. Inc. v. CEPHEID, 905 F.3d 1363, 
1370–71 (Fed. Cir. 2018) (finding a method of diagnosis using DNA amplifica-
tion and associated DNA primers to both be patent ineligible). 
 211. Cf. Julia Carbone et al., DNA Patents and Diagnostics: Not a Pretty Pic-
ture, 28 NATURE BIOTECH. 784, 785 (2011) (“[T]here is no evidence to suggest 
that exclusive licensing is as important in the field of diagnostic testing as in 
therapeutics in creating products that would not otherwise exist.”) (emphasis 
added). 
 212. See, e.g., discussion infra Section III.C. 
 213. See, e.g., discussion infra Section III.E. 
 214. See discussion of method of treatment patents supra Section II.C. 
 215. Limelight Networks, Inc. v. Akamai Techs., Inc., 572 U.S. 915, 919 
(2014) (citing Muniauction, Inc. v. Thomson Corp., 532 F.3d 1318, 1329 (Fed. 
Cir. 2008)). 
 216. Cf. id. at 921–22 (“The Federal Circuit held in Muniauction that a 
method’s steps have not all been performed as claimed by the patent unless they 
are all attributable to the same defendant, either because the defendant actu-
ally performed those steps or because he directed or controlled others who per-
formed them.”). 
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which gives immunity for violations of some medical activity pa-
tents to licensed medical practitioners,217 though § 
287(c)(2)(A)(iii) specifically limits this immunity to allow liabil-
ity for “the practice of a process in violation of a biotechnology 
patent.”218 There is no statutory definition of what constitutes a 
“biotechnology patent,” but the section’s legislative history indi-
cates that the provision likely would allow a physician to be lia-
ble for infringement of an siRNA-based patented method of 
treatment.219 However, patentees may be reluctant to sue physi-
cians given that lawsuits against doctors for infringing method 
of treatment patents have historically prompted extremely neg-
ative reactions from the public.220 At least to this extent, patent-
ees may likely prefer to sue generic manufacturers for indirect 
infringement under §§ 271(b)–(c) rather than for direct infringe-
ment under § 271(a).221 
Liability under § 271(b) requires actual knowledge of the in-
fringed patent.222 Moreover, under § 271(b), the patentee has the 
burden of proving that the alleged infringer “possessed specific 
intent to encourage another’s infringement.”223 The specific in-
tent for inducement liability “require[s] more than just intent to 
cause the acts that produce direct infringement.”224 Likewise, 
 
 217. See 35 U.S.C. § 287(c) (1999). 
 218. 35 U.S.C. § 287(c)(2)(A)(iii) (2011). 
 219. Cf. H.R. REP. NO. 104-863, at 854 (1996) (Conf. Rep.) (“For the purposes 
of [§ 287(c)(2)(iii)], the definition of the term ‘biotechnology patent’ includes a 
patent on a ‘biotechnological process’ as defined in 35 U.S.C. § 103(b), as well as 
a patent on a process of making or using biological materials, including treat-
ment using those materials, where those materials have been manipulated ex 
vivo at the cellular or molecular level.”). 
 220. See Sally Squires, AMA Condemns Patents for Medical Procedures, 
WASH. POST (June 20, 1995), https://www.washingtonpost.com/archive/poli-
tics/1995/06/20/ama-condemns-patents-for-medical-procedures/b339653c-e4fa-
4991-ad41-e762edc52b16/; see also Katherine J. Strandburg, Legal but Unac-
ceptable: Pallin v. Singer and Physician Patenting Norms 1, 16 (NYU Ctr. for 
L., Econ. & Org., Working Paper No. 14-42, 2014) (describing the passage of § 
287(c) as in response to Pallin v. Singer, a well-publicized suit concerning the 
violation of a medical procedure patent). 
 221. See generally 35 U.S.C. § 271. 
 222. Glob.-Tech Appliances, Inc. v. SEB S.A., 563 U.S. 754, 765–66 (2011). 
 223. DSU Med. Corp. v. JMS Co., 471 F.3d 1293, 1304 (Fed. Cir. 2006) (citing 
Manville Sales Corp. v. Paramount Sys., Inc., 917 F.2d 544, 553 (Fed. Cir. 
1990)). 
 224. Id. at 1306. 
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deliberate indifference cannot prompt liability for indirect in-
fringement.225 Reasonable belief of non-infringement has also 
defeated inducement liability.226 The Federal Circuit has limited 
inducement liability for the prescription of a generic compound 
for infringing off-label uses.227 The District Court for the District 
of Delaware has expanded on the intent requirement specifically 
in regard to a “method of treatment” patent, holding that induce-
ment liability can be avoided if a generic manufacturer does not 
list the infringing use on the label of the drug.228 The court fur-
ther held that even where the relevant generic label indicated 
that it could be used to treat a disease identified in a patented 
method of treatment, inducement liability cannot be found 
where the direct infringer did not read the label.229 Because of 
these hurdles, § 271(b) may not present a realistic opportunity 
for siRNA patentees to collect damages from generic manufac-
turers of the compounds used in patented methods of treatment. 
However, there is a possibility that an siRNA patentee could 
successfully sue a generic manufacturer for contributory in-
fringement under § 271(c). Like § 271(b), liability under  § 271(c) 
 
 225. See Glob.-Tech Appliances, Inc., 563 U.S. at 770 (“[I]n demanding only 
‘deliberate indifference’ to that risk, the Federal Circuit’s test does not require 
active efforts by an inducer to avoid knowing about the infringing nature of the 
activities.”). 
 226. Ecolab, Inc. v. FMC Corp., 569 F.3d 1335, 1351 (Fed. Cir.), amended on 
reh’g in part, 366 F. App’x 154 (Fed. Cir. 2009) (holding that a jury could per-
missibly conclude that the defendant “reasonably believed” they were not in-
fringing the patent at issue). 
 227. Takeda Pharm. U.S.A., Inc. v. W.-Ward Pharm. Corp., 785 F.3d 625, 
633 (Fed. Cir. 2015) (holding that “speculation or even proof that some, or even 
many, doctors would prescribe” a generic drug in a way that infringes a method 
of treatment patent is likely insufficient for § 271(b) liability). 
 228. GlaxoSmithKline LLC v. Teva Pharm. USA, Inc., 313 F. Supp. 3d 582, 
592 (D. Del. 2018) (holding that there cannot be inducement liability for selling 
a drug used to infringe a method of treatment, because the generic’s “label omit-
ted from its label the language contained on [the non-generic’s] label concerning 
the use” of the drug to perform the patented method of treatment); see also 
Takeda Pharm. U.S.A., Inc., 785 F.3d at 633. 
 229. See GlaxoSmithKline LLC, 313 F. Supp. 3d at 591 (“As Dr. McCullough 
concedes that he did not read Teva’s label, he cannot state, for instance, that he 
noticed or otherwise knew what (if anything) that label said about using carve-
dilol to treat CHF.”); but see AstraZeneca LP v. Apotex, Inc., 633 F.3d 1042, 
1060 (Fed. Cir. 2010) (holding that a generic label that provides specific treat-
ment instructions, such as how many times a day to use the relevant drug or 
what type of doses to utilize, may be sufficient evidence of intent for inducement 
liability). 
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requires actual knowledge of the infringed patent.230 The pa-
tentee’s burden of proof for liability under § 271(c) includes 
showing that “the accused products are not staple articles of 
commerce suitable for no substantial non-infringing uses.”231 
Presumably, an siRNA used in a patented method of treatment 
would not be a “staple article of commerce” and would have no 
real use outside of the patented method due to the specificity of 
siRNA-mediated gene silencing.232 Though contributory in-
fringement is generally not recommended as a primary method 
of patent enforcement,233 this remains a potential avenue of re-
covery against a generic manufacturer. 
In short, siRNA therapeutics are likely restricted to a class 
of patents enforceable for direct infringement only against phy-
sicians, with any theory of liability for generic manufacturers in-
stead relying on contributory infringement. Because pharma-
ceutical companies value strong patent protection when 
determining which products to develop,234 the limited enforce-
ment strategies available to patentees could discourage the de-
velopment of novel siRNA therapeutics. 
B. THE FEDERAL CIRCUIT’S STANDARD MAY BE A SOURCE OF 
CONFUSION 
Compounding the aforementioned problems facing siRNA 
patentees (as well as nucleotide patentees more generally), the 
Federal Circuit has used a nebulous, and perhaps counter-intu-
itive, definition of “nucleotide structure.” Ambry rejected DNA 
primers in spite of evidence that primers are single-stranded 
and “single-stranded DNA cannot be found in the human 
 
 230. Glob.-Tech Appliances, Inc., 563 U.S. at 764 (citing Aro Mfg. Co. v. Con-
vertible Top Replacement Co., 377 U.S. 476, 488 (1964)). 
 231. See, e.g., In re Bill of Lading Transmission & Processing Sys. Patent 
Litig., 681 F.3d 1323, 1331 (Fed. Cir. 2012). 
 232. Cf. Golden Blount, Inc. v. Robert H. Peterson Co., 438 F.3d 1354, 1363 
(Fed. Cir. 2006) (finding contributory infringement for sale of a fireplace burner 
that was not a “staple article of commerce and was especially made” for use with 
the plaintiff’s patented invention); see Lam et al., supra note 45, at 255 (describ-
ing siRNAs as “extremely useful for targeting single gene disorders”). 
 233. Cf. James Yang, Claim Drafting Tip: Focus on Direct, Not Indirect In-
fringement, OC PATENT L. (Sept. 14, 2015), https://ocpatentlawyer.com/claim-
drafting-tip-focus-on-direct-not-indirect-infringement/ (discouraging the use of 
claims that only capture indirect infringement). 
 234. See Roin, supra note 144, at 514 (“Moreover, it is well known that phar-
maceutical companies generally refuse to develop new drugs unless they have 
strong patent protection over them.”). 
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body.”235 Ambry cites Myriad for the proposition that “separating 
[DNA] from its surrounding genetic material is not an act of in-
vention,” but does not explain how single-stranded primers are 
analogous to isolating a gene.236 Further, Ambry held that pri-
mers do not have a “unique structure, different from anything 
found in nature” potentially on that basis that the primers at 
issue have an identical sequence to a gene found in nature.237 
Likewise, the Federal Circuit in Roche rejected arguments 
that Roche’s primers were structurally unique on the basis of 3’ 
hydroxyl groups that are not present in M. tuberculosis DNA.238 
The court held that “distinction unavailing” and further that the 
appropriate “subject matter inquiry of primer claims hinges on 
comparing a claimed primer to its corresponding DNA segment 
on the chromosome—not the whole chromosome,” citing a pas-
sage from Ambry “emphasizing the appropriate comparison be-
ing” that of nucleotide sequences.239 Ultimately, the Federal Cir-
cuit has left the meaning of “nucleotide structure” indeterminate 
and uncertain. 
Two potential working definitions of “nucleotide structure” 
arise from a survey of Federal Circuit precedent. It is possible 
that the Federal Circuit’s definition of “nucleotide structure” in-
cludes some, but not all, elements of nucleotide structure in the 
patent eligibility analysis.240 If that is the case, the court has 
failed to specifically enumerate which elements are useful to the 
determination of patent eligibility, likely creating a recurring 
 
 235. Univ. of Utah Research Found. v. Ambry Genetics, 774 F.3d 775, 760 
(Fed. Cir. 2014). 
 236. Id. at 759 (quoting Ass’n for Molecular Pathology v. Myriad Genetics, 
Inc., 569 U.S. 576, 590 (2013)) (internal quotation marks omitted). 
 237. Cf. id. at 761 (citing Myriad Genetics, 569 U.S. at 589) (“A DNA struc-
ture with a function similar to that found in nature can only be patent eligible 
as a composition of matter if it has a unique structure, different from anything 
found in nature . . . [p]rimers do not have such a different structure and are 
patent ineligible.”). 
 238. See Roche Molecular Sys., Inc. v. CEPHEID, 905 F.3d 1363, 1369–70 
(Fed. Cir. 2018) (“Roche’s primers are indistinguishable from their correspond-
ing nucleotide sequences on the naturally occurring MTB rpoB gene.”). 
 239. Id. at 1370 (citing Ambry, 774 F.3d at 760–61). 
 240. Cf., e.g., Ambry, 774 F.3d at 760 (“Myriad argues that primers are in 
fact not naturally occurring because single-stranded DNA cannot be found in 
the human body. But, as the Supreme Court made clear, ‘separating [DNA] from 
its surrounding genetic material is not an act of invention.’”). 
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source of uncertainty for patentees.241 Alternatively, it is possi-
ble that the Federal Circuit treats “nucleotide structure” as 
meaning “nucleotide sequence.”242 This definition is divorced 
from the conventional scientific understanding of DNA structure 
as the molecular structure of a DNA molecule243 and seems par-
ticularly insensible in view of the Supreme Court’s scientifically-
nuanced handling of nucleotide patenting in Myriad.244 Hope-
fully, future holdings on the subject will clarify which definition 
of “nucleotide structure” the Federal Circuit uses for patent eli-
gibility analysis. 
C. RE-THINKING AMBRY GENETICS 
One way to bring siRNA therapeutics further into patent el-
igibility would be to revise the holding of Ambry, as has been 
suggested by Judge O’Malley of the Federal Circuit.245 Specifi-
cally, Judge O’Malley has postulated that the Federal Circuit 
erred in treating a nucleotide sequence as its structure for the 
purposes of patent eligibility.246 Allowing unique chemical struc-
tures not found in nature, like the free 3’ hydroxyl groups of Am-
bry and Roche, to cure patent ineligibility of some nucleotide se-
quences may also carve out a space for the patenting of siRNA 
as compositions of matter. As discussed in Part I of this note, 
siRNA can have a number of structural features that are not 
 
 241. Cf., e.g., Roche Molecular Sys., 905 F.3d at 1370 (emphasizing that the 
appropriate subject matter comparison for DNA primers is between the primers 
and the naturally occurring sequence). 
 242. See id. at 1377 (O’Malley, J., concurring) (implying the majority con-
flated sequence with structure); cf., e.g., id. at 1371 (Fed. Cir. 2018) (“We hold 
that the primers before us are indistinguishable from their corresponding nu-
cleotide sequences on the naturally occurring DNA, and that the primer claims, 
therefore, are patent-ineligible . . . .”). 
 243. See, e.g., The Structure of DNA, BOISE ST. U., 
http://cs.boisestate.edu/~amit/teaching/342/lab/structure.html (last visited 
Mar. 5, 2019) (describing the structure of DNA in terms of its molecular struc-
ture). 
 244. Cf. Myriad Genetics, 569 U.S. at 594–95 (distinguishing genomic DNA 
from cDNA for the purposes of patent eligibility). 
 245. See Roche Molecular Sys., 905 F.3d at 1381 (O’Malley, J., concurring) 
(“I believe, accordingly, that we should revisit our conclusion in BRCA1 en 
banc.”). 
 246. See id. (“[A]s the record in this case reveals, a finding that the two [DNA 
molecules] have identical sequences does not entirely resolve the question of 
whether they are structurally identical because structure is not defined solely 
by nucleotide sequence.”). 
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present in naturally occurring mRNA sequences, such as being 
double-stranded or having single-strand overhangs.247 
D. THE REST OF THE PATENT ACT IS CAPABLE OF PREVENTING 
OVERBROAD CLAIMS 
In adopting restrictive interpretations of 35 U.S.C. § 101, 
the courts have expressed a concern about the patenting of “basic 
tools of scientific and technological work.”248 In fact, this princi-
ple was cited in both Myriad249 and Ambry.250 However, a num-
ber of alternatives exist within the Patent Act to prevent over-
broad patents that extend to basic tools of scientific research. 35 
U.S.C. § 112, for instance, acts to prevent “pure functional claim-
ing” that can extend a patent’s scope to an idea or a basic re-
search tool.251 Likewise, 35 U.S.C. § 102 incorporates the doc-
trine of “inherency” which “allows determination of whether 
subject matter that is not taught in the single reference was 
nonetheless known in the field of the invention.”252 Modern in-
terpretations of the doctrine are able to broadly exclude claim 
elements present in the prior art from patenting, including those 
that may not have been recognized by persons of ordinary 
 
 247. See generally Lam et al., supra note 45, at 254 (comparing siRNA design 
with miRNA design as a therapeutic gene agent).; see also discussion of siRNA 
structure supra Section I.B 
 248. Gottschalk v. Benson, 409 U.S. 63, 67 (1972). 
 249. See Ass’n of Molecular Pathology v. Myriad Genetics, Inc., 569 U.S. 576, 
589 (2013) (quoting Mayo Collaborative Servs. v. Prometheus Labs., Inc., 566 
U.S. 66, 71 (2012)) (“We have long held that [§ 101] contains an important im-
plicit exception: Laws of nature, natural phenomena, and abstract ideas are not 
patentable. Rather, they are the basic tools of scientific and technological work 
that lie beyond the domain of patent protection.”) (quotations and citations 
omitted). 
 250. See Univ. of Utah Research Found. v. Ambry Genetics, 774 F.3d 775, 
764 (Fed. Cir. 2014) (citing Myriad Genetics, 569 U.S.at 589) (“[I]t is antithetical 
to the patent laws to allow these basic building blocks of scientific research to 
be monopolized.”). 
 251. See, e.g., Aristocrat Techs. Australia Pty Ltd. v. Int’l Game Tech., 521 
F.3d 1328, 1333 (Fed. Cir. 2008) (“The point of [§§ 112(a)–(b)] is to avoid pure 
functional claiming.”); cf. Med. Instrumentation & Diagnostics Corp. v. Elekta 
AB, 344 F.3d 1205, 1211 (Fed. Cir. 2003) (“If the specification is not clear as to 
the structure that the patentee intends to correspond to the claimed function, 
then the patentee has not paid that price but is rather attempting to claim in 
functional terms unbounded by any reference to structure in the specification.”). 
 252. Schering Corp. v. Geneva Pharm., Inc., 348 F.3d 992, 995 (Fed. Cir. 
2003) (“The analytic tool of ‘inherency’ allows determination of whether subject 
matter that is not taught in the single reference was nonetheless known in the 
field of the invention [and therefore anticipated].”). 
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skill.253 Further, some scholars have argued that the second step 
of the Alice framework254 overlaps with the obviousness inquiry 
under § 103,255 thereby implying that patents on “basic tools of 
scientific and technological work” can be prevented through § 
103 instead of § 101.256 Effectively, there are several alternatives 
to § 101 within the Patent Act available to prevent the patenting 
of basic tools of scientific and technological work under a more 
“relaxed” interpretation of Ambry that would allow for siRNA to 
be patent eligible as a composition of matter. 
E. NON-PATENT SIRNA MARKET EXCLUSIVITY COULD 
INCENTIVIZE INVESTMENT 
In lieu of patent protection, Congress could extend an alter-
native form of limited market exclusivity to siRNA therapeutics. 
In theory, such a grant of exclusivity could resemble the already 
existing grant supplied to so-called “orphan drugs” (those that 
treat rare diseases).257 Historically, pharmaceutical companies 
have viewed orphan drugs as unprofitable and avoided investing 
in their development.258 Congress successfully incentivized the 
development of orphan drugs259 by conferring on them a seven-
 
 253. In re Cruciferous Sprout Litig., 301 F.3d 1343, 1349 (Fed. Cir. 2002) 
(quoting MEHL/Biophile Int’l Corp. v. Milgraum, 192 F.3d 1362, 1365 (Fed. Cir. 
1999)) (“Inherency is not necessarily coterminous with the knowledge of those 
of ordinary skill in the art. Artisans of ordinary skill may not recognize the in-
herent characteristics or functioning of the prior art.”) (internal quotation 
marks omitted). 
 254. That is, whether the claim elements are “well-understood, routine, or 
conventional.” Alice Corp. Pty. v. CLS Bank Int’l, 573 U.S. 208, 225 (2014) (quot-
ing Mayo, 566 U.S. at 73) (internal quotation marks omitted). 
 255. See Paxton M. Lewis, The Conflation of Patent Eligibility and Obvious-
ness: Alice’s Substitution of Section 103, 2017 UTAH ONLAW: THE UTAH L. REV. 
ONLINE SUPPLEMENT 13, 14 (2017) (“[Step two of the Alice framework] already 
takes place under section 103 for obviousness . . . .”). 
 256. Cf. id. at 27 (illustrating how some Federal Circuit judges have used 
obviousness and patent eligibility interchangeably). 
 257. OFFICE OF INSPECTOR GEN., DEP’T OF HEALTH & HUMAN SERVS., OEI-
09-00-00380, THE ORPHAN DRUG ACT IMPLEMENTATION AND IMPACT (2001), at 
1 (defining orphan drugs in the U.S. as those that treat “a disease that affects 
fewer than 200,000 people”). 
 258. See id. at 4 (finding the drugs used to treat for small patient populations 
unprofitable). 
 259. See id. at 7 (“The Orphan Drug Act’s incentives . . . motivate[s] compa-
nies to develop orphan products.”). 
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year period of exclusive marketing rights.260 In the same way, 
conferring a limited term of market exclusivity onto siRNA ther-
apeutics could serve to incentivize their development in place of 
patent rights.261 Congress has more recently passed the Biolog-
ics Price Competition Innovation Act (“BPCIA”), which grants a 
twelve-year term of non-patent marketing exclusivity to certain 
protein-based therapeutics.262 The text of the BPCIA does not 
extend exclusivity to nucleotides, but given that the act does 
grant exclusivity to other biomolecular therapeutics,263 legisla-
tion granting non-patent exclusivity to siRNA therapeutics 
would likely be uncontroversial.264 
 
 260. See id. at 4 (providing three incentives including 7-year market exclu-
sivity to sponsors of approved orphan products); see generally CTR. FOR DRUG 
EVALUATION & RES., U.S. FOOD & DRUG ADMIN., PATENTS AND EXCLUSIVITY 
(2015), at 2, https://www.fda.gov/downloads/drugs/developmentapprovalpro-
cess/smallbusinessassistance/ucm447307.pdf (describing the statutory require-
ments for orphan drug exclusivity). 
 261. Cf. ORPHAN DRUG ACT IMPLEMENTATION AND IMPACT, supra note 257, 
at 7 (describing the positive effect of market exclusivity on orphan drug devel-
opment); cf. Angélique McCall & Gene Quinn, The FDA Process, Patents and 
Market Exclusivity, IP WATCHDOG (Mar. 12, 2017), http://www.ipwatch-
dog.com/2017/03/12/fda-process-patents-market-exclusivity/id=79305/ (“A pa-
tent is not the only path to exclusivity. In fact, the FDA characterizes patents 
and ‘exclusivity’ separately.”). 
 262. See 42 U.S.C. § 262(k)(7)(A)(2019); see also U.S. FOOD & DRUG. ADMIN., 
NEW AND REVISED DRAFT Q&AS ON 
BIOSIMILAR DEVELOPMENT AND THE BPCI ACT (REVISION 2), at 12 [hereinafter 
NEW AND REVISED DRAFT Q&AS] (describing the BPCIA as amending the defi-
nition of “biological product” at § 262(i) to include certain protein-based thera-
peutics). 
 263. See 42 U.S.C. § 262(i)(1); see also NEW AND REVISED DRAFT Q&AS, su-
pra note 262, at 12 (interpreting “protein” as used in the BPCIA “to mean any 
alpha amino acid polymer with a specific defined sequence that is greater than 
40 amino acids in size”). 
 264. Because the BPCIA was passed as a component of the Patient Protec-
tion and Affordable Care Act, at least one commentator has expressed concern 
about its continued viability in light of the recent Texas v. United States deci-
sion. See Kyle Faget, ACA Strike-Down: Salvaging the BPCIA via Severability, 
FOLEY & LARDNER LLP: HEALTH CARE LAW TODAY (Jan. 2, 2019), 
https://www.healthcarelawtoday.com/2019/01/02/aca-strike-down-salvaging-
the-bpcia-via-severability/; see also Texas v. United States, 340 F. Supp. 3d 579, 
614 (N.D. Tex. 2018) (finding the individual mandate of the Patient Protection 
and Affordable Care Act unconstitutional in light of the Tax Cuts and Jobs Act 
and further finding the individual mandate inseverable). To the extent that 
Congress may have to create new legislation if they want to maintain a system 
of limited market exclusivity for protein therapeutics, they would have an op-
portunity to include related protections for siRNA therapeutics. See id. at 614. 
2020] SILENCING INNOVATION 369 
 
CONCLUSION 
This note has illustrated the problems of patent eligibility 
that both would-be and current siRNA patentees may face. Like 
traditional therapeutics, siRNA therapeutics have a costly re-
search and development cycle, as well as a costly FDA-approval 
process.265 Therefore, limiting the patent protection available to 
siRNAs could seriously stifle their development.266 Further, 
siRNA therapeutics could represent a $1.81 billion market by 
2025,267 and have numerous advantages over conventional ther-
apeutics,268 illustrating both the economic and medical needs to 
encourage would-be patentees to invest in their development. In 
fact, many diseases are likely to remain untreatable without 
some kind of nucleotide-based therapy option.269 
Under the dual holdings of Ambry and Myriad, it seems 
likely that siRNA therapeutics will only be patent eligible as 
methods of treatment, unless that option is foreclosed by poten-
tial Supreme Court review.270 As discussed in Part III of this 
note,271 limiting the patent eligibility of siRNA therapeutics to 
methods of treatment may limit enforcement options against ge-
neric manufacturers and thereby may discourage development 
of siRNA therapeutics.272 This note has identified two options to 
provide a form of market exclusivity to siRNA therapeutics in 
order to incentivize their private development: adopting an al-
ternative interpretation of Ambry that relaxes current § 101 
standards to allow patenting of siRNA as compositions of matter, 
 
 265. See discussion of the FDA-approval process, pharmaceutical invest-
ment, and siRNA, supra Section I.H. 
 266. Roin, supra note 144, at 505 (“[P]harmaceutical companies are rarely 
willing to develop drugs without patent protection.”). 
 267. Antisense & RNAi, supra note 143. 
 268. See, e.g., Bullis, supra note 52. 
 269. See, e.g., Novartis, supra note 15 (“[M]ost of the proteome is . . . undrug-
gable.”). 
 270. See Vanda Pharm., Inc. v. W.-Ward Pharm. Int’l Ltd., 887 F.3d 1117, 
1136 (Fed. Cir. 2018), petition for cert. filed, 87 U.S.LW. 3279 (U.S. Jan. 17, 
2019) (No. 18-817). 
 271. See generally discussion of the role of effective market exclusivity in 
driving investment in pharmaceutical-sector products supra Sections I.H, III.A, 
and III.E. 
 272. Cf. Yang, supra note 233 (describing reasons for avoiding claims that 
only capture indirect infringement). 
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as discussed in Section III.C,273 and extending non-patent mar-
ket exclusivity rights to siRNA therapeutics, as discussed in Sec-
tion III.E.274 
 
 273. See discussion supra Section III.C. 
 274. See discussion supra Section III.E. 
